Tirzepatide (15 mg Vial) Dosage Protocol

Research dosing guide for higher-concentration Tirzepatide reconstitution and progressive titration for extended metabolic regulation research.

Quickstart Highlights

Operating through dual GLP-1 and GIP receptor pathways, Tirzepatide is a 39-amino-acid compound that promotes insulin secretion in response to elevated glucose, decreases glucagon output, decelerates gastric transit, and lessens food intake drive. Its roughly 5-day half-life facilitates weekly subcutaneous dosing schedules.

Reconstitute: Add 2.0 mL bacteriostatic water → 7.5 mg/mL concentration
Titration schedule: 2.5 mg → 5 mg → 7.5 mg → 10 mg+ weekly over 16+ weeks
Easy measuring: At 7.5 mg/mL, calculations differ from 5 mg/mL concentration
Storage: Lyophilized: −20 °C (−4 °F) in dry, dark conditions; after reconstitution: 2–8 °C (35.6–46.4 °F), protected from light, use within 28 days

Dosing & Reconstitution Guide

Titration schedule for once-weekly subcutaneous administration

Weekly Subcutaneous Protocol (2 mL = 7.5 mg/mL)

Phase	Weekly Dose	Units (per injection)
Weeks 1–4	2.5 mg	33 units (0.33 mL)
Weeks 5–8	5 mg	67 units (0.67 mL)
Weeks 9–12	7.5 mg	100 units (1.0 mL)
Weeks 13–16	10 mg	67 units × 2 injections at different sites

Note: Higher doses (12.5–15 mg/week) may follow if tolerated.

Reconstitution Steps

Draw 2.0 mL bacteriostatic water using a sterile syringe
Inject slowly down the vial wall; avoid foaming
Gently swirl/roll until dissolved (do not shake)
Label with reconstitution date and refrigerate
Use within 28 days of reconstitution

Storage Guidelines

Lyophilized vial: −20 °C (−4 °F) in dry, dark conditions
After reconstitution: 2–8 °C (35.6–46.4 °F), protected from light
Shelf life: 28 days once reconstituted; do not freeze reconstituted solution

⚠️ Research & Educational Purposes Only